These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 18560222)

  • 21. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
    Ceppi P; Rapa I; Lo Iacono M; Righi L; Giorcelli J; Pautasso M; Billè A; Ardissone F; Papotti M; Scagliotti GV
    Int J Cancer; 2012 Apr; 130(8):1777-86. PubMed ID: 21618517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
    Wu MF; Hsiao YM; Huang CF; Huang YH; Yang WJ; Chan HW; Chang JT; Ko JL
    J Thorac Oncol; 2010 Aug; 5(8):1143-51. PubMed ID: 20559153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells.
    Giovannetti E; Mey V; Nannizzi S; Pasqualetti G; Marini L; Del Tacca M; Danesi R
    Mol Pharmacol; 2005 Jul; 68(1):110-8. PubMed ID: 15795320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.
    Tekle C; Giovannetti E; Sigmond J; Graff JR; Smid K; Peters GJ
    Br J Cancer; 2008 Sep; 99(5):750-9. PubMed ID: 18728666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
    Mey V; Giovannetti E; De Braud F; Nannizzi S; Curigliano G; Verweij F; De Cobelli O; Pece S; Del Tacca M; Danesi R
    Br J Cancer; 2006 Aug; 95(3):289-97. PubMed ID: 16868547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
    Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
    Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine.
    Rodenbach M; Eyol E; Seelig MH; Berger MR
    J Cancer Res Clin Oncol; 2005 May; 131(5):289-99. PubMed ID: 15657768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer.
    Wilson PM; LaBonte MJ; Lenz HJ; Mack PC; Ladner RD
    Mol Cancer Ther; 2012 Mar; 11(3):616-28. PubMed ID: 22172489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line.
    Wang Y; Zhao R; Goldman ID
    Biochem Pharmacol; 2003 Apr; 65(7):1163-70. PubMed ID: 12663051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.
    Sigmond J; Backus HH; Wouters D; Temmink OH; Jansen G; Peters GJ
    Biochem Pharmacol; 2003 Aug; 66(3):431-8. PubMed ID: 12907242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.
    Markova B; Hähnel PS; Kasper S; Herbertz S; Schuler M; Breitenbuecher F
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):545-54. PubMed ID: 22203472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytotoxic effects of pemetrexed in gastric cancer cells.
    Kim JH; Lee KW; Jung Y; Kim TY; Ham HS; Jong HS; Jung KH; Im SA; Kim TY; Kim NK; Bang YJ
    Cancer Sci; 2005 Jun; 96(6):365-71. PubMed ID: 15958060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
    Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
    Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
    J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced apoptosis by pemetrexed and simvastatin in malignant mesothelioma and lung cancer cells by reactive oxygen species-dependent mitochondrial dysfunction and Bim induction.
    Hwang KE; Kim YS; Hwang YR; Kwon SJ; Park DS; Cha BK; Kim BR; Yoon KH; Jeong ET; Kim HR
    Int J Oncol; 2014 Oct; 45(4):1769-77. PubMed ID: 25096993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gli as a novel therapeutic target in malignant pleural mesothelioma.
    Li H; Lui N; Cheng T; Tseng HH; Yue D; Giroux-Leprieur E; Do HT; Sheng Q; Jin JQ; Luh TW; Jablons DM; He B
    PLoS One; 2013; 8(3):e57346. PubMed ID: 23483902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
    Toyokawa G; Takenoyama M; Hirai F; Toyozawa R; Inamasu E; Kojo M; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Shimokawa M; Seto T; Ichinose Y
    Int J Clin Oncol; 2014 Aug; 19(4):601-6. PubMed ID: 24158772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
    Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
    Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K
    Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.